195 related articles for article (PubMed ID: 17989424)
1. Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans.
Li C; Liu T; Cui X; Uss AS; Cheng KC
J Biomol Screen; 2007 Dec; 12(8):1084-91. PubMed ID: 17989424
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability.
Lau YY; Chen YH; Liu TT; Li C; Cui X; White RE; Cheng KC
Drug Metab Dispos; 2004 Sep; 32(9):937-42. PubMed ID: 15319334
[TBL] [Abstract][Full Text] [Related]
3. Development of a high-throughput in vitro assay using a novel Caco-2/rat hepatocyte system for the prediction of oral plasma area under the concentration versus time curve (AUC) in rats.
Cheng KC; Li C; Hsieh Y; Montgomery D; Liu T; White RE
J Pharmacol Toxicol Methods; 2006; 53(3):215-8. PubMed ID: 16181794
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
6. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
[TBL] [Abstract][Full Text] [Related]
7. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans.
Li C; Liu T; Broske L; Brisson JM; Uss AS; Njoroge FG; Morrison RA; Cheng KC
Biochem Pharmacol; 2008 Dec; 76(12):1757-64. PubMed ID: 18835257
[TBL] [Abstract][Full Text] [Related]
8. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a).
Usansky HH; Sinko PJ
J Pharmacol Exp Ther; 2005 Jul; 314(1):391-9. PubMed ID: 15833900
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
10. Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human?
Turco L; Catone T; Caloni F; Di Consiglio E; Testai E; Stammati A
Toxicol In Vitro; 2011 Feb; 25(1):13-20. PubMed ID: 20732406
[TBL] [Abstract][Full Text] [Related]
11. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs.
Föger F; Kopf A; Loretz B; Albrecht K; Bernkop-Schnürch A
Amino Acids; 2008 Jun; 35(1):233-41. PubMed ID: 17726639
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
13. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
14. Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: comparison with permeabilities from artificial membrane (PAMPA) assay, in silico and caco-2 assay, for 65 drugs.
Hallifax D; Turlizzi E; Zanelli U; Houston JB
Eur J Pharm Sci; 2012 Apr; 45(5):570-4. PubMed ID: 22214813
[TBL] [Abstract][Full Text] [Related]
15. A comparison of pharmacokinetics between humans and monkeys.
Akabane T; Tabata K; Kadono K; Sakuda S; Terashita S; Teramura T
Drug Metab Dispos; 2010 Feb; 38(2):308-16. PubMed ID: 19910513
[TBL] [Abstract][Full Text] [Related]
16. Prediction of human pharmacokinetics--gastrointestinal absorption.
Fagerholm U
J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent pharmacokinetics of a new Na+/H+ exchanger inhibitor KR-33028 in rats.
Kim YH; Yoo SD; Kim YS; Lee KH; Lee HS
Biopharm Drug Dispos; 2007 Nov; 28(8):423-9. PubMed ID: 17828714
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model.
Paixão P; Gouveia LF; Morais JA
Int J Pharm; 2012 Jun; 429(1-2):84-98. PubMed ID: 22449410
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a rat model versus a physiologically based extraction test for assessing phenanthrene bioavailability from soils.
Pu X; Lee LS; Galinsky RE; Carlson GP
Toxicol Sci; 2004 May; 79(1):10-7. PubMed ID: 14976340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
